Bariatric surgery found to be more cost effective than GLP-1 RAs alone
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are cost effective in the long term only when combined with bariatric surgery,...
top of page
Browse by category
Search
GLP-1 medications for teens with type 2 diabetes and obesity frequently denied by insurance companies
Health insurance companies often deny coverage for GLP-1 receptor agonists (GLP1Ra) that treat children and teens with obesity and type 2...
AstraZeneca enters obesity market with $2b deal for GLP-1 candidate
AstraZeneca has signed an exclusive license agreement with Shanghai-based biotech Eccogene for ECC5004, an early-stage investigational...
AGA: Not all patients should cease taking GLP-1 RAs prior to endoscopy
The American Gastroenterological Association (AGA) has released a rapid clinical practice update addressing the management of patients...
First participant dosed in Terns’ trial of TERN-601 oral GLP-1ra for treatment of obesity
Terns Pharmaceuticals has announced that the first participant has been dosed in the Phase 1 clinical trial of TERN-601, the company’s...
Innovent starts Phase 2 Clinical Trial of mazdutide in Chinese adults with obesity
Innovent Biologics has announced that the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical...
Browse by tag
bottom of page